Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
Ropivacaine is indicated in adult patients for the induction of regional or local anesthesia for surgery or acute pain management.
Nanjing Maternity and Child Health Care Hospital, Nanjing, Jiangsu, China
Changi General Hospital, Singapore, Singapore
General Surgery Ward, Poriya, The Lower Galilee, Israel
Seoul National University Bundang Hospital, Sungnam, Gyungido, Korea, Republic of
CCOM-Hôpitaux Universitaires de Strasbourg, Illkirch-Graffenstaden, France
Anesthesia, Critical Care and Pain Medicine - University of Parma, Parma, PR, Italy
Rush Oak Park Hospital, Oak Park, Illinois, United States
Department of anaesthesiology, Bispebjerg Hospital, Copenhagen, Denmark
Istituto Ortopedico G. Pini, Milan, Milano, Italy
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.